Pharmaceutical Wholesaler And Supply

By Author: Laxmi Upasna
Total Articles: 8
Comment this article

The government is committed to making India one of the world's leading destinations for end-to-end drug discovery and innovation and pharmaceutical suppliers by 2020. Although India has achieved the distinction of being the world's No. 1 supplier of low-cost Pharmaceutical Suppliers, in recent years, a toxic brew of misguided government policy and shortsighted business practices has crippled our efforts to become a drug discovery and innovation powerhouse, even while jeopardizing our access to foreign markets due to quality issues. After much deliberation, the government ruled in favor of 100% foreign direct investment in the pharmaceutical industry. This is a positive move and will allow India to invest in R&D, enhance local capabilities and find solutions to endemic health problems. 2013 also saw the success of several public-private partnerships between government and MNCs in the pharmaceutical industry. Such partnerships hold great potential when it comes to larger healthcare access in India.


The crisis in the clinical research industry that peaked this year needs to be resolved without delay. India ...
... has the potential to become a global hub for clinical trial supply for new chemical entities, unless vetted by the Union health secretary, is not the answer. To grow, both in terms of value and volume, India needs to strengthen its commercial capabilities, realize its R&D prowess and collaborate with stakeholders within and outside the industry to drive access and shape the market. Three years ago, the then-President Pratibha Patil declared this to be India's "Decade of Innovation". However, we have since lost sight of an important fact: promoting innovation means protecting our innovators and creators, attracting world-class R&D, and creating and sustaining high-quality future jobs through robust protection of intellectual property (IP) rights. Today, India is primarily a branded generics supplier with limited focus on innovation and research. While we excel at developing copies of offpatent drugs, we lag far behind other member-countries of the World Trade Organization in new drug development. India experienced a significant increase in the number of patents granted and in force immediately following the implementation of the TRIPS agreement in 2005, but since then, there has been a pronounced fall. This fall coincides with a wider weakening of India's IP environment and hurts domestic inventors as well as foreign companies.


The entire Pharma Wholesale industry will see a change in the days to come. Pharma wholesalers holding licenses will be now allowed to speak to drug manufacturers directly to get their drugs which they can then sell to the retailers. At the moment pharma companies are selling their products directly to stockists who sell it to the retailers. This arrangement had been the norm for the past few years and was supported by All India Organization of Chemists & Druggists (AIOCD) which controlled it. Though the trade move was opposed by the drug manufacturers and the end users. Even the new system has not found many takers with the pharma companies as they now will have to deal with many wholesale agents which may add up to their costs. The system needed to be changed after the Competition Commission of India ordered the AIOCD to stop engaging in acts that violated the competition act.br>

Author Bio:


For the past 3 years I have been writing informative and high quality articles on pharmaceutical company. In the above article have covered topics such as pharmaceutical suppliers, clinical trial supply and pharma wholesale.